Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection.

Key Stats

• Today's Range: C$12.72 to C$13.21
• 50-Day Range: C$8.10 to C$13.88
• 52-Week Range: C$7.59 to C$14.24
• Volume: 1,030 shs
• Average Volume: 1,286 shs
• Market Capitalization: C$441.85 million
• P/E Ratio: N/A
• Dividend Yield: 2.02%
• Price Target: N/A
• Consensus Rating: Strong Buy

Fennec Pharmaceuticals Stock Analysis - MarketRank™

Fennec Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Fennec Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fennec Pharmaceuticals is -43.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fennec Pharmaceuticals is -43.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fennec Pharmaceuticals has a P/B Ratio of 11.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FRX.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Fennec Pharmaceuticals pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fennec Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Fennec Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Fennec Pharmaceuticals insiders have sold 108.38% more of their company's stock than they have bought. Specifically, they have bought C$100,614.00 in company stock and sold C$209,659.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.79% of the stock of Fennec Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 11/07/2024
• Today: 6/04/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:FRX
• CIK: N/A
• Web: fennecpharma.com
• Phone: +1-919-6364530
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 21.07
• P/E Growth: N/A
• Net Income: -C$800.44 thousand
• Net Margins: -17.22%
• Pretax Margin: N/A
• Return on Equity: -58.09%
• Return on Assets: 8.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.98
• Quick Ratio: 10.17

Sales & Book Value

• Annual Sales: C$51.00 million
• Price / Sales: 8.66
• Cash Flow: C$1.09 per share
• Price / Cash Flow: 11.66
• Book Value: C$1.09 per share
• Price / Book: 11.62

Miscellaneous

• Outstanding Shares: 34,737,000
• Free Float: N/A
• Market Cap: C$441.85 million
• Optionable: Not Optionable
• Beta: 3.52